• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

To arm the im­mune sys­tem for sus­tained at­tack against HIV, NIH sci­en­tists take to vi­ral vec­tors

6 years ago
R&D
Cell/Gene Tx

J&J's fa­vorite CAR-T de­vel­op­er, cur­rent­ly owned by a Chi­nese CRO, is lay­ing the ground­work for US IPO

6 years ago
Financing
Cell/Gene Tx

Which top-lev­el Bio­gen ex­ec has test­ed pos­i­tive for coro­n­avirus? WSJ nar­rows the lot­tery to 4, in­clud­ing the CEO

6 years ago
Coronavirus

Is­rael’s Arkin Hold­ings launch­es sec­ond biotech fund, worth $140 mil­lion

6 years ago
Financing

Gates Foun­da­tion, Mas­ter­card, Well­come launch coro­n­avirus treat­ment ac­cel­er­a­tor as out­break deep­ens

6 years ago
Coronavirus

Ver­sant woos Mor­phoSys' ex-CSO to its boom­ing dis­cov­ery en­gine, with big plans for new star­tups

6 years ago
People
Financing

Bris­tol My­ers backs a Eu­ro­pean VC's record-set­ting biotech ven­ture fund, which tops out at $600M

6 years ago
R&D
Pharma

An­oth­er myo­statin pro­gram com­busts, but Ac­celeron has plen­ty in the pipeline

6 years ago
R&D

Nine new coro­n­avirus cas­es are tied to the Bio­gen out­break — as in­fec­tions spread to 'close con­tact­s'

6 years ago
People
Pharma

Unum racks up yet an­oth­er FDA hold as it twists its way through a re­struc­tur­ing, look­ing for a fresh start with a ...

6 years ago
R&D

In­ovio files for $50M of­fer­ing amid Covid-19 vac­cine hunt; Zy­dus Cadi­la signs on with XO­MA on IL-2 deal

6 years ago
News Briefing

Chi­nese biotech bags $50M+ for I/O, au­toim­mune work, start­ing with ALK5 in­hibitor

6 years ago
Financing
China

Bris­tol My­ers flunks front­line mul­ti­ple myelo­ma tri­al, turn­ing at­ten­tion to cell ther­a­py

6 years ago
R&D
Cell/Gene Tx

ACC scraps its flag­ship event in Chica­go as Covid-19 fears spread faster than the virus

6 years ago
Coronavirus

With pos­i­tive key tri­al, Kala Phar­ma's dry eye drug Ey­su­vis em­u­lates ap­proval path set by Xi­idra

6 years ago
R&D

Bio­phar­ma stocks take a beat­ing as eco­nom­ic tur­moil takes its toll — but some play­ers with coro­n­avirus ef­forts ...

6 years ago
Coronavirus

Neil Wood­ford in the game to buy back his for­mer un­list­ed port­fo­lio that's prov­ing hard to sell — re­ports

6 years ago
Financing
Deals

FDA ap­proves ex-No­var­tis drug for Cush­ing’s dis­ease

6 years ago
Pharma

Tri­fec­ta of clin­i­cal stage biotechs un­veil IPO plans, brav­ing Wall Street's coro­n­avirus pan­ic

6 years ago
Financing

Mit­subishi joins Ei­sai, 3SBio's bet on mul­ti­spe­cif­ic an­ti­bod­ies, up­ping Num­ab's Se­ries B haul to $23M+

6 years ago
Financing

As Bio­gen grap­ples with coro­n­avirus cri­sis, Big Phar­mas like Eli Lil­ly, Take­da hun­ker down, tell staffers to work ...

6 years ago
Pharma
Coronavirus

Tal­ly of coro­n­avirus cas­es at Bio­gen spikes by 15 on Sun­day — and Cowen says one in­fect­ed ex­ec at­tend­ed big ...

6 years ago
Coronavirus

Bio­gen man­dates quar­an­tine, new work-from-home mea­sures for most staffers as coro­n­avirus trig­gers 5 more in­fec­tions

6 years ago
Coronavirus

Coro­n­avirus up­date: Trump signs $8.3B spend­ing bill in­to law; Pfiz­er con­sid­ers mR­NA vac­cine pact with BioN­Tech

6 years ago
News Briefing
First page Previous page 846847848849850851852 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.